Jelena Veselinovic, MD
Psychiatry · Yonkers, NYNPI 1073625661
Payments from drug & device makers
Across 196 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$895
- Lundbeck LLC$880
- Otsuka America Pharmaceutical, Inc.$413
- Alkermes, Inc.$271
- E.r. Squibb & Sons, L.L.C.$227
- plus $681 from 9 others
What the payments were for
- Food & beverage$4,405100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $1,038 |
| Johnson & Johnson | 39 | $895 |
| Lundbeck LLC | 40 | $880 |
| Otsuka America Pharmaceutical, Inc. | 18 | $413 |
| Alkermes, Inc. | 11 | $271 |
| E.r. Squibb & Sons, L.L.C. | 9 | $227 |
| Teva Pharmaceuticals USA, Inc. | 8 | $211 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $148 |
| Indivior Inc. | 6 | $102 |
| Sunovion Pharmaceuticals Inc. | 4 | $81 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $43 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $13 |
How this compares
$4,405 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 53 | $909 |
| Quetiapine Fumarate | 50 | $691 |
| Risperidone | 73 | $633 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 26 | $632 |
| Clozapine | 13 | $546 |
| Sertraline Hcl | 74 | $365 |
| Benztropine Mesylate | 38 | $363 |
| Zolpidem Tartrate | 41 | $302 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $228 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $203 |
| Mirtazapine | 23 | $133 |
| Clonazepam | 50 | $131 |
| Escitalopram Oxalate | 25 | $120 |
| Topiramate | 13 | $97 |
| Lorazepam | 27 | $87 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Yonkers
- Yadagiri ChepuruYonkers$963K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.